STAT3 and neoplasm: Interestingly, Dosch et al. have recently demonstrated that dasatinib plus erlotinib inhibits STAT3 whilst enhancing micro-vessel density and inducing stromal remodelling in PDAC tumours using a Ptf1acre/+; LSL-KrasG12D/+; Tgfbr2flox/flox transgenic mouse model [111].